RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.

LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.

Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.

Zotatifin is a selective eukaryotic initiation factor 4A (eIF4A) inhibitor.

Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.